ARCT 154
Alternative Names: ARCT-154; Kostaive; VBC-COV19-154Latest Information Update: 14 Sep 2025
At a glance
- Originator Arcturus Therapeutics
- Developer Arcturus Therapeutics; Meiji Seika Pharma; Vinbiocare Biotechnology
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 28 Aug 2025 Meiji Seika Pharma received manufacturing and marketing approval in Japan for a 2-dose lyophilized presentation of KOSTAIVE®
- 11 Aug 2025 Meiji Seika Pharma anticipates approval for 2-dose lyophilized vaccine presentation in Japan by third or fourth quarter of 2025
- 11 Aug 2025 Arcturus Therapeutics expects an approval decision in the US in 2026